Mesothelioma Helping

Licensing Opportunity Available to Pharmaceutical Companies

Med Services Europe reports progress in partnering prescription pharmaceuticals registered for Hormone Replacement Therapy.

Zurich, Switzerland (PRWEB) April 4, 2006 -- Med Services Europe GmbH, a “Virtual European Headquarters” announced progress out-licensing a portfolio of prescription pharmaceutical products registered in several European markets for Hormone Replacement Therapy. (http://www.MedServicesEurope.com).

“Distributors have now been signed for several markets,” explained Dr Emmer. “However, rights are still available for other world-wide markets including several in Eastern and Western Europe and the Mid-East”.

Dr. Emmer explained further about the opportunity that this portfolio presents to pharmaceutical companies “The distributors that we have signed understand that the market for HRT products is very large and growing and is hungry for new launches. They agree that this portfolio offers many interesting advantages for the market”.

Dr Emmer encourages pharmaceutical companies to learn more about the opportunity to in-license this portfolio of products. “This is a unique opportunity to obtain marketing rights to an exciting portfolio of products, which are currently registered in several European markets”
Pharmaceutical companies interested in obtaining more information are encouraged to contact Dr Emmer at Med Services Europe in Switzerland.

About Med Services Europe:
Med Services Europe GmbH is located in Zurich, Switzerland and specializes in Sales, Marketing and Business Development for Pharmaceutical and Medical manufacturers. Med Services acts as a virtual European Headquarters by developing and managing distribution networks for its clients. For more information: http://www.MedServicesEurope.com or +41764249963

###

Press Contact: Dr. Gene Emmer
Company Name: MED SERVICES EUROPE GMBH
Email: email protected from spam bots
Phone: +41764249963
Website: http://www.medserviceseurope.com

# posted by PPC Meso @ 9:40 AM